Results 21 to 30 of about 6,020,192 (375)

Well‐being on supportive techniques in amyotrophic lateral sclerosis: from neurologists' perspective

open access: yesAnnals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1874-1883, December 2022., 2022
Abstract Objective To investigate intercultural neurologists' perception of well‐being in patients with amyotrophic lateral sclerosis (ALS) using gastrostomy (PEG), non‐invasive, and/or invasive ventilation (NIV/IV) and to analyse the determinants and impact on the management of the above medical interventions (MIs).
Krzysztof Barć   +7 more
wiley   +1 more source

Clinical heterogeneity in a family with flail arm syndrome and review of hnRNPA1‐related spectrum

open access: yesAnnals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1910-1917, December 2022., 2022
Abstract Objective Flail arm syndrome (FAS) is one of the atypical subtypes of amyotrophic lateral sclerosis (ALS). Mutations in hnRNPA1 encoding heterogeneous nuclear ribonucleoprotein (hnRNP) A1 are a rare genetic cause of ALS. Herein, marked clinical heterogeneity of FAS in a pedigree with a known hnRNPA1 variant was described to raise early ...
Xiaochen Han   +5 more
wiley   +1 more source

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition

open access: yesMultiple Sclerosis, 2020
Background: High-quality epidemiologic data worldwide are needed to improve our understanding of disease risk, support health policy to meet the diverse needs of people with multiple sclerosis (MS) and support advocacy efforts.
Clare Walton   +14 more
semanticscholar   +1 more source

COVID‐19 and the risk of Alzheimer's disease, amyotrophic lateral sclerosis, and multiple sclerosis

open access: yesAnnals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1953-1961, December 2022., 2022
Abstract Background The coronavirus disease 2019 (COVID‐19) pandemic has had an unprecedented impact on the healthcare system, economy, and society. Studies have reported that COVID‐19 may cause various neurologic symptoms, including cognitive impairment.
Hanyu Zhang, Zengyuan Zhou
wiley   +1 more source

Cognitive rehabilitation in multiple sclerosis: Three digital ingredients to address current and future priorities

open access: yesFrontiers in Human Neuroscience, 2023
Multiple sclerosis (MS) is a neurological chronic disease with autoimmune demyelinating lesions and one of the most common disability causes in young adults.
Andrea Tacchino   +5 more
doaj   +1 more source

Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

open access: yesAnnals of Neurology, 2021
This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID‐19) in people with multiple sclerosis (PwMS).
M. Sormani   +15 more
semanticscholar   +1 more source

The anterior nucleus of the thalamus plays a role in the epileptic network

open access: yesAnnals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 2010-2024, December 2022., 2022
Abstract Objectives We investigated both the metabolic differences and interictal/ictal discharges of the anterior nucleus of the thalamus (ANT) in patients with epilepsy to clarify the relationship between the ANT and the epileptic network. Methods Nineteen patients with drug‐resistant epilepsy who underwent stereoelectroencephalography were studied ...
Hao Yan   +9 more
wiley   +1 more source

Multiple sclerosis

open access: yesMedicine, 2008
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) and the most common cause of disability amongst young adults. The majority of patients present with a relapsing-remitting illness, characterized by discrete episodes of focal neurological deficit with temporal and anatomical dispersion in the CNS.
Wakerley, B, Nicholas, R, Malik, O
openaire   +6 more sources

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy

open access: yesNeurology and Therapy, 2023
Background Some multiple sclerosis (MS) disease-modifying therapies (DMTs) impair responses to vaccines, emphasizing the importance of understanding COVID-19 vaccine immune responses in people with MS (PwMS) receiving different DMTs.
Aliya Jaber   +7 more
doaj   +1 more source

Multiple sclerosis [PDF]

open access: yesMental Health Clinician, 2019
Abstract Multiple sclerosis is a chronic, unpredictable, and disabling disease. Significant advances have been made in recent years supporting an earlier, more accurate, diagnosis and have led to more than 15 disease-modifying therapies approved by the Food and Drug Administration for relapsing forms of multiple sclerosis.
Shilpa Klocke, Nicole Hahn
openaire   +2 more sources

Home - About - Disclaimer - Privacy